At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 411 enrolled
Drug / intervention
AZD8233 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia
In Brief
A Phase 2 clinical trial evaluating AZD8233 and Placebo for Hyperlipidaemia. Completed, enrolled 411 participants across 66 sites in 8 countries.
Detailed Summary
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidaemia
CountriesCzechia, Denmark, Hungary, Netherlands, Poland, Slovakia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedJul 2021
Primary CompletionJul 2022
TodayJul 2026
First PostedJul 16, 2021
Enrollment StartJul 7, 2021
Primary CompletionJul 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.0 years ago
Interventions
AZD8233drug
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Placebodrug
Placebo solution